-5.9 C
New York
Friday, December 5, 2025

Eli Lilly’s obesity pill remains a viable rival to Novo’s oral Wegovy despite data that underwhelmed investors

Eli Lilly’s stock is still recovering after the drugmaker released trial data earlier this month on its closely watched obesity pill that …

This post was originally published on this site

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

149,858FansLike
396,312FollowersFollow
2,470SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x